# Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

> **NCT01311713** · PHASE1,PHASE2 · TERMINATED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 45 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** CEP-9722

## Key facts

- **NCT ID:** NCT01311713
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05-02
- **Primary completion:** 2013-10-16
- **Final completion:** 2013-10-16
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01311713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01311713, "Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01311713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*